S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate|
|GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy|
|GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma|
|UPDATE: Drug stocks drive European markets higher (2014/4/22)|
|Drug stocks drive European markets higher (2014/4/22)|
|UPDATE: Glaxo, AstraZeneca lead U.K. stocks to two-week high (2014/4/22)|
|UPDATE: Glaxo, AstraZeneca lead gains in U.K. stocks (2014/4/22)|
|Glaxo, AstraZeneca lead gains in U.K. stocks (2014/4/22)|
|UPDATE: European stocks ease as BNP, Glaxo lose ground (2014/4/30)|
|Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments|
Click above to view more mutual fund data and stats for gsk - GlaxoSmithKline PLC ADR.